<DOC>
	<DOCNO>NCT00232999</DOCNO>
	<brief_summary>This study design evaluate effectiveness nebulized IVX-0142 , novel anti-allergic drug , inhibit allergen-induced airway narrow patient allergic asthma relate increased sensitivity airway substance , well investigate possible anti-inflammatory effect drug airway .</brief_summary>
	<brief_title>Efficacy/Safety Study Nebulized IVX-0142 , Novel Antiallergic Drug , Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Mild stable allergic asthma Positive skinprick test least one common aeroallergen Positive methacholine challenge Positive allergeninduced early latephase airway bronchoconstriction General good health Lung diseases mild allergic asthma History symptom cardiovascular disease , significant neurologic disease , and/or clinically significant autoimmune disease Chronic use asthma medication short intermediate betaagonists ipratropium Use tobacco product within one year start study smoke history &gt; 10 pack year If female , pregnant lactate positive pregnancy test screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Allergic asthma</keyword>
	<keyword>Allergen challenge</keyword>
	<keyword>Bronchial hyperresponsiveness</keyword>
</DOC>